Lv21
120 积分 2023-11-08 加入
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
16天前
已完结
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
6个月前
已完结
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
6个月前
已完结
Endpoints in prostate cancer clinical trials
7个月前
已完结
Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
10个月前
已完结
皖公网安备34019202002308
